Kewaunee Scientific (KEQU) 10-Q 15 Mar 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jan. 31, 2019	Mar. 11, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jan. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	KEQU
Entity Registrant Name	KEWAUNEE SCIENTIFIC CORP /DE/
Entity Central Index Key	0000055529
Current Fiscal Year End Date	--04-30
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Common Stock, Shares Outstanding		2,746,598

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Income Statement [Abstract]
Net sales	$ 32,372	$ 38,190	$ 111,802	$ 113,542
Costs of products sold	27,142	29,791	91,325	90,411
Gross profit	5,230	8,399	20,477	23,131
Operating expenses	5,305	5,971	17,031	16,360
Operating earnings (loss)	(75)	2,428	3,446	6,771
Other income	186	179	500	524
Interest expense, net	(76)	(78)	(258)	(226)
Earnings before income taxes	35	2,529	3,688	7,069
Income tax expense (benefit)	20	1,581	803	3,164
Net earnings	15	948	2,885	3,905
Less: net earnings attributable to the noncontrolling interest	37	35	86	120
Net earnings (loss) attributable to Kewaunee Scientific Corporation	$ (22)	$ 913	$ 2,799	$ 3,785
Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders
Basic (in dollars per share)	$ (0.01)	$ 0.33	$ 1.02	$ 1.39
Diluted (in dollars per share)	$ (0.01)	$ 0.32	$ 1	$ 1.36
Weighted average number of common shares outstanding
Basic (in shares)	2,744	2,722	2,741	2,717
Diluted (in shares)	2,794	2,784	2,799	2,772

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Statement of Comprehensive Income [Abstract]
Net earnings	$ 15	$ 948	$ 2,885	$ 3,905
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustments	496	203	(617)	49
Change in fair value of cash flow hedge	(1)	12	4	30
Other comprehensive income (loss)	495	215	(613)	79
Comprehensive income, net of tax	510	1,163	2,272	3,984
Less: comprehensive income attributable to the noncontrolling interest	37	35	86	120
Comprehensive income attributable to Kewaunee Scientific Corporation	$ 473	$ 1,128	$ 2,186	$ 3,864

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Treasury Stock	Retained Earnings	Accumulated Other Comprehensive Income (Loss)
Beginning balance at Apr. 30, 2017	$ 43,461	$ 6,789	$ 2,695	$ (53)	$ 40,349	$ (6,319)
Net earnings attributable to Kewaunee Scientific Corporation	1,148				1,148
Other comprehensive loss	83					83
Cash dividends paid	(406)				(406)
Stock options exercised	9	1	8
Stock based compensation	52		52
Ending balance at Jul. 31, 2017	44,347	6,790	2,755	(53)	41,091	(6,236)
Beginning balance at Apr. 30, 2017	43,461	6,789	2,695	(53)	40,349	(6,319)
Net earnings attributable to Kewaunee Scientific Corporation	3,785
Other comprehensive loss	79
Ending balance at Jan. 31, 2018	46,278	6,821	2,947	(53)	42,803	(6,240)
Beginning balance at Jul. 31, 2017	44,347	6,790	2,755	(53)	41,091	(6,236)
Net earnings attributable to Kewaunee Scientific Corporation	1,724				1,724
Other comprehensive loss	(219)					(219)
Cash dividends paid	(462)				(462)
Stock options exercised	(1)	15	(16)
Stock based compensation	126	4	122
Ending balance at Oct. 31, 2017	45,515	6,809	2,861	(53)	42,353	(6,455)
Net earnings attributable to Kewaunee Scientific Corporation	913				913
Other comprehensive loss	215					215
Cash dividends paid	(463)				(463)
Stock options exercised	0	12	(12)
Stock based compensation	98		98
Ending balance at Jan. 31, 2018	46,278	6,821	2,947	(53)	42,803	(6,240)
Beginning balance at Apr. 30, 2018	47,730	6,841	3,006	(53)	43,836	(5,900)
Net earnings attributable to Kewaunee Scientific Corporation	1,407				1,407
Other comprehensive loss	(384)					(384)
Cash dividends paid	(465)				(465)
Stock options exercised		13	(13)
Stock based compensation	106	7	99
Ending balance at Jul. 31, 2018	48,611	6,861	3,092	(53)	44,995	(6,284)
Beginning balance at Apr. 30, 2018	47,730	6,841	3,006	(53)	43,836	(5,900)
Net earnings attributable to Kewaunee Scientific Corporation	2,799
Other comprehensive loss	(613)
Ending balance at Jan. 31, 2019	48,990	6,869	3,342	(53)	45,345	(6,513)
Cumulative adjustment for accounting change, net of tax	217				217
Beginning balance at Jul. 31, 2018	48,611	6,861	3,092	(53)	44,995	(6,284)
Net earnings attributable to Kewaunee Scientific Corporation	1,414				1,414
Other comprehensive loss	(724)					(724)
Cash dividends paid	(521)				(521)
Stock options exercised		8	(8)
Stock based compensation	140		140
Ending balance at Oct. 31, 2018	48,920	6,869	3,224	(53)	45,888	(7,008)
Net earnings attributable to Kewaunee Scientific Corporation	(22)				(22)
Other comprehensive loss	495					495
Cash dividends paid	(521)				(521)
Stock based compensation	118		118
Ending balance at Jan. 31, 2019	$ 48,990	$ 6,869	$ 3,342	$ (53)	$ 45,345	$ (6,513)

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended				6 Months Ended
	Jan. 31, 2019	Jul. 31, 2018	Jan. 31, 2018	Jul. 31, 2017	Oct. 31, 2018	Oct. 31, 2017
Statement of Stockholders' Equity [Abstract]
Cash dividends paid (in usd per share)	$ 0.19	$ 0.17	$ 0.17	$ 0.15	$ 0.19	$ 0.17
Stock options exercised (in shares)	5,800	9,250	6,859	500		15,241

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Current Assets:
Cash and cash equivalents	$ 10,771	$ 9,716
Restricted cash	606	1,242
Receivables, less allowance; $361; $384, on each respective date	27,929	32,660
Inventories	16,672	18,549
Prepaid expenses and other current assets	3,778	2,224
Total Current Assets	59,756	64,391
Property, plant and equipment, at cost	56,791	54,648
Accumulated depreciation	(41,589)	(39,987)
Net Property, Plant and Equipment	15,202	14,661
Deferred income taxes	1,676	1,869
Other assets	2,928	4,162
Total Other Assets	4,604	6,031
Total Assets	79,562	85,083
Current Liabilities:
Short-term borrowings and interest rate swaps	5,118	3,885
Current portion of long-term debt and lease obligations	1,184	1,167
Accounts payable	11,106	14,754
Employee compensation and amounts withheld	1,954	3,810
Deferred revenue	1,450	1,884
Other accrued expenses	2,894	2,116
Total Current Liabilities	23,706	27,616
Long-term debt and lease obligations	526	1,264
Accrued pension and deferred compensation costs	5,480	7,465
Income taxes payable	339	546
Total Liabilities	30,051	36,891
Commitments and Contingencies
Stockholders’ Equity:
Common stock, $2.50 par value, Authorized – 5,000 shares; Issued – 2,747 shares; 2,736 shares; – Outstanding – 2,744 shares; 2,733 shares, on each respective date	6,869	6,841
Additional paid-in-capital	3,342	3,006
Retained earnings	45,345	43,836
Accumulated other comprehensive loss	(6,513)	(5,900)
Common stock in treasury, at cost, 3 shares, on each date	(53)	(53)
Total Kewaunee Scientific Corporation Stockholders’ Equity	48,990	47,730
Noncontrolling interest	521	462
Total Stockholders’ Equity	49,511	48,192
Total Liabilities and Stockholders’ Equity	$ 79,562	$ 85,083

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Statement of Financial Position [Abstract]
Allowance for receivables	$ 361	$ 384
Common stock, par value	$ 2.50	$ 2.50
Common stock, shares authorized	5,000,000	5,000,000
Common stock, shares issued	2,747,000	2,736,000
Common stock, shares outstanding	2,744,000	2,733,000
Treasury stock, shares	3,000	3,000

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities:
Net earnings	$ 2,885	$ 3,905
Adjustments to reconcile net earnings to net cash provided by (used in) operating activities:
Depreciation	1,908	2,104
Bad debt provision	57	71
Stock based compensation expense	393	276
Provision for deferred income taxes	355	639
Change in assets and liabilities:
Decrease (increase) in receivables	4,674	(1,025)
Decrease (increase) in inventories	990	(2,790)
(Decrease) increase in accounts payable and other accrued expenses	(4,879)	2,035
Decrease in deferred revenue	(434)	(3,847)
Other, net	(1,415)	(2,013)
Net cash provided by (used in) by operating activities	4,534	(645)
Cash flows from investing activities:
Capital expenditures	(2,290)	(1,907)
Net cash used in investing activities	(2,290)	(1,907)
Cash flows from financing activities:
Dividends paid	(1,507)	(1,331)
Dividends paid to holders of noncontrolling interest in subsidiaries	(51)	(74)
Proceeds from short-term borrowings	46,103	44,639
Repayments on short-term borrowings	(44,870)	(43,452)
Payments on long-term debt and lease obligations	(880)	(626)
Net proceeds from exercise of stock options	(29)	8
Net cash used in financing activities	(1,234)	(836)
Effect of exchange rate changes on cash and cash equivalents	(591)	118
Increase (decrease) in cash, cash equivalents and restricted cash	419	(3,270)
Cash, cash equivalents and restricted cash, beginning of period	10,958	13,941
Cash, cash equivalents and restricted cash, end of period	$ 11,377	$ 10,671

Financial Information

Financial Information	9 Months Ended
	Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Financial Information	Financial Information The unaudited interim condensed consolidated financial statements of Kewaunee Scientific Corporation (the “Company”) have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “Commission”). Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, although the Company believes that the disclosures are adequate to make the information presented not misleading. These interim condensed consolidated financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair presentation of these financial statements and should be read in conjunction with the consolidated financial statements and notes included in the Company’s 2018 Annual Report on Form 10-K. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. The condensed consolidated balance sheet as of April 30, 2018 included in this interim period filing has been derived from the audited financial statements at that date, but does not include all of the information and related notes required by generally accepted accounting principles (GAAP) for complete financial statements. The preparation of the interim condensed consolidated financial statements requires management to make certain estimates and assumptions that affect reported amounts and disclosures. Actual results could differ from those estimates. Change in Accounting Principle and Second Quarter Financial Statements During the second quarter of fiscal year 2019, the Company changed its method of accounting for its Domestic segment’s inventory from the last-in, first-out (LIFO) method to the first-in, first out (FIFO) method. The Company’s prior year condensed consolidated balance sheet as of April 30, 2018 and statements of stockholders’ equity for the three- and six-month periods ended October 30, 2018 presented in the second quarter of fiscal year 2019 were not adjusted for the retrospective application of the change in method of accounting to FIFO. Note E in the second quarter financial statements did include a presentation of the adjusted condensed consolidated balance sheet as of April 30, 2018, including the adjustments made for the accounting change. The prior year consolidated balance sheet and statement of stockholders’ equity have been corrected in the current presentation for the third quarter of fiscal 2019. All prior periods presented herein have been retrospectively adjusted to apply the new method of accounting. See Note E for more information on the change in inventory accounting method.

Revenue Recognition

Revenue Recognition	9 Months Ended
	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition The Company recognizes revenue when control of a good or service promised in a contract (i.e., performance obligation) is transferred to a customer. Control is obtained when a customer has the ability to direct the use of and obtain substantially all of the remaining benefits from that good or service. The majority of the Company’s revenues are recognized over time as the customer receives control as the Company performs work under a contract. However, a portion of the Company’s revenues are recognized at a point-in-time as control is transferred at a distinct point in time per the terms of a contract. Performance Obligations A performance obligation is a distinct good or service or bundle of goods and services that is distinct or a series of distinct goods or services that are substantially the same and have the same pattern of transfer. The Company identifies performance obligations at the inception of a contract and allocates the transaction price to individual performance obligations to reasonably reflect the Company’s performance in transferring control of the promised goods or services to the customer. The Company has elected to treat shipping and handling as a fulfillment activity instead of a separate performance obligation. The following are the primary performance obligations identified by the Company: Laboratory Furniture The Company principally generates revenue from the manufacture of custom laboratory, healthcare, and technical furniture and infrastructure products (herein referred to as “laboratory furniture”). The Company’s products include steel, wood, and laminate furniture, fume hoods, biological safety cabinets, laminar flow and ductless hoods, adaptable modular and column systems, moveable workstations and carts, epoxy resin worksurfaces, sinks, and accessories and related design services. Customers can benefit from each piece of laboratory furniture on its own or with resources readily available in the market place such as separately purchased installation services. Each piece of laboratory furniture does not significantly modify or customize other laboratory furniture, and the pieces of laboratory furniture are not highly interdependent or interrelated with each other. The Company can, and frequently does, break portions of contracts into separate “runs” to meet manufacturing and construction schedules. As such, each piece of laboratory furniture is considered a separate and distinct performance obligation. The majority of the Company’s products are customized to meet the specific architectural design and performance requirements of laboratory planners and end users. The finished laboratory furniture has no alternative use to the Company and the Company has an enforceable right to payment for performance completed to date. As such, revenue from the sales of customized laboratory furniture is recognized over time once the customization process has begun, using the units-of-production output method to measure progress towards completion. There is not a material amount of work-in-process for which the customization process has begun at the end of a reporting period. The Company believes this output method most reasonably reflects the Company’s performance because it directly measures the value of the goods transferred to the customer. For standardized products sold by the Company, revenue is recognized when control transfers, which is typically freight on board (“FOB”) shipping point. Warranties All orders contain a standard warranty that warrants that the product is free from defects in workmanship and materials under normal use and conditions for a limited period of time. Due to the nature and quality of the Company’s products, any warranty issues have historically been determined in a relatively short period after the sale, have been infrequent in nature, and have been immaterial to the Company’s financial position and results of operations. The Company’s standard warranties are not considered a separate and distinct performance obligation as the Company does not provide a service to customers beyond assurance that the covered product is free of initial defects. Costs of providing these short term assurance warranties are immaterial and, accordingly, are expensed as incurred. Extended separately priced warranties are available which can last up to five years. Extended warranties are considered separate performance obligations as they are individually priced options providing assurances that the products are free of defects. Installation Services The Company sometimes performs installation services for customers. The scope of installation services primarily relates to setting up and ensuring the proper functioning of the laboratory furniture. In certain markets, the Company may provide a broader range of installation services involving the design and installation of the laboratory’s mechanical services. Installation services can be, and often are, performed by third parties and thus may be distinct from the Company’s products. Installation services create or enhance assets that the customer controls as the installation services are provided.As such, revenue from installation services is recognized over time, as the installation services are performed using the cost input method, as there is a direct relationship between the Company’s inputs and the transfer of control by means of the performance of installation services to the customer. Custodial Services It is common in the laboratory and healthcare furniture industries for customers to request delivery at specific future dates, as products are often to be installed in buildings yet to be constructed. Frequently, customers will request the manufacture of these products prior to the customer’s ability or readiness to receive the product due to various reasons such as changes to or delays in the construction of the building. As such, from time to time our customers require us to provide custodial services for their laboratory furniture. Custodial services are frequently provided by third parties and do not significantly alter the other goods or services covered by the contract and as such are considered a separate and distinct performance obligation. Custodial services are simultaneously received and consumed by the customer and as such revenue from custodial services is recognized over time using a straight-line time-based measure of progress towards completion, because the Company’s services are provided evenly throughout the performance period. Payment Terms and Transaction Prices The Company's contracts with customers are fixed-priced and do not contain variable consideration or a general right of return or refund. The Company's contracts with customers contain terms typical for our industry, including withholding a portion of the transaction price until after the goods or services have been transferred to the customer (i.e. “retainage”). The Company does not recognize this as a significant financing component because the primary purpose of retainage is to provide the customer with assurance that the Company will perform its obligations under the contract, rather than to provide financing to the customer. Allocation of Transaction Price The Company's contracts with customers may cover multiple goods and services, such as differing types of laboratory furniture and installation services. For these arrangements, each good or service is evaluated to determine whether it represents a distinct performance obligation. The total transaction price is then allocated to the distinct performance obligations based on their relative standalone selling price at the inception of the arrangement. If available, the Company utilizes observable prices for goods or services sold separately to similar customers in similar circumstances to determine its relative standalone selling price. Otherwise, list prices are used if they are determined to be representative of standalone selling prices. If neither of these methods are available at contract inception, such as when the Company does not sell the product or service separately, judgment may be required and the Company determines the standalone selling price using one, or a combination of, the adjusted market assessment or expected cost-plus margin approaches. Practical Expedients Used Accounting Standards Codification 606 - Revenue from Contracts with Customers ("ASC 606") permits the use of practical expedients under certain conditions. The Company has elected the following practical expedients allowed under ASC 606: • Under the modified retrospective approach, the Company elected to reassess revenue recognition under ASC 606 for only those contracts open as of the adoption date. • The portfolio approach was applied in evaluating the accounting for the cost of obtaining a contract. • Payment terms with the Company's customers which are one year or less are not considered a significant financing component. • The Company excludes from revenues taxes it collects from customers that are assessed by a government authority. This is primarily relevant to domestic sales but also includes taxes on some international sales which are also excluded from the transaction price. • The Company's incremental cost to obtain a contract is limited to sales commissions. The Company applies the practical expedient to expense commissions as incurred for contracts having a duration of one year or less. Sales commissions related to contracts with a duration of greater than one year are immaterial to the Company’s consolidated financial position and results of operations and are also expensed as incurred. Disaggregated Revenue A summary of net sales transferred to customers at a point in time and over time for the three and nine months ended January 31, 2019 is as follows (in thousands): Three Months Ended January 31, 2019 Domestic International Total Over Time $ 24,414 $ 7,155 $ 31,569 Point in Time 803 — 803 $ 25,217 $ 7,155 $ 32,372 Nine Months Ended January 31, 2019 Domestic International Total Over Time $ 86,973 $ 19,893 $ 106,866 Point in Time 4,936 — 4,936 $ 91,909 $ 19,893 $ 111,802 Contract Balances The closing and opening balances of contract assets and liabilities arising from contracts with customers were $1,450,000 at January 31, 2019 and $1,884,000 at April 30, 2018. The timing of revenue recognition, billings and cash collections results in accounts receivable, unbilled receivables, and deferred revenue on the condensed consolidated balance sheets. In general, the Company receives payments from customers based on a billing schedule established in its contracts. Unbilled receivables represent amounts earned which have not yet been billed in accordance with contractually stated billing terms. Accounts receivable are recorded when the right to consideration becomes unconditional and the Company has a right to invoice the customer. Deferred revenue relates to payments received in advance of performance under the contract. Deferred revenue is recognized as revenue as (or when) the Company performs under the contract. During the three and nine months ended January 31, 2019 , changes in contract assets and liabilities were not materially impacted by any other factors. Approximately 100% of the contract liability balance at April 30, 2018 is expected to be recognized as revenue during fiscal year 2019 and 14% and 95% of this amount was recognized during the three and nine months ended January 31, 2019 , respectively. ASC 606 adoption impact Under ASC 606, sales consisting of customized products sold to customers for which revenue was previously recognized at a point in time now meet the criteria of a performance obligation satisfied over time. These contracts consist of customized laboratory furniture engineered or tailored to meet the customer’s requirements. In the event the customer cancels the contract, the Company will have no alternative use for and cannot economically repurpose the laboratory furniture, and the Company has the right to payment for performance completed to date. This change results in accelerated recognition of revenue and increases the balance of contract assets compared to the previous revenue recognition standard. The Company adopted ASC 606 on May 1, 2018 using the modified retrospective approach and elected to reassess revenue recognition under ASC 606 for only those contracts open as of the adoption date, which resulted in a cumulative effect adjustment to increase retained earnings, net of tax, of $217,000 . Comparative information for prior periods has not been restated and continues to be reported under the accounting standards in effect for those periods presented. The Company elected to reflect the aggregate effect of all contract modifications that occurred before the beginning of the earliest period presented in determining the transaction price, identifying the satisfied and unsatisfied performance obligations and allocating the transaction price to the satisfied and unsatisfied performance obligations for the modified contract at transition. The effects of these elections were immaterial. The following tables summarize the impact of adopting ASC 606 on the condensed consolidated statements of operations: Three Months Ended January 31, 2019 ($ in thousands, except per share amounts) As Reported Adjustments Balance Without Adoption of ASC 606 Net sales $ 32,372 $ (1,668 ) $ 30,704 Costs of products sold 27,142 (1,519 ) 25,623 Gross profit 5,230 (149 ) 5,081 Operating expenses 5,305 6 5,311 Operating loss (75 ) (155 ) (230 ) Other income 186 — 186 Interest expense (76 ) — (76 ) Earnings (loss) before income taxes 35 (155 ) (120 ) Income tax expense (benefit) 20 (46 ) (26 ) Net earnings (loss) 15 (109 ) (94 ) Net earnings attributable to the noncontrolling interest 37 — 37 Net earnings (loss) attributable to Kewaunee Scientific Corporation $ (22 ) $ (109 ) $ (131 ) Basic Loss Per Share $ (0.01 ) $ (0.04 ) $ (0.05 ) Diluted Loss Per Share $ (0.01 ) $ (0.04 ) $ (0.05 ) Nine Months Ended January 31, 2019 ($ in thousands, except per share amounts) As Reported Adjustments Balance Without Adoption of ASC 606 Net sales $ 111,802 $ (1,720 ) $ 110,082 Costs of products sold 91,325 (1,169 ) 90,156 Gross profit 20,477 (551 ) 19,926 Operating expenses 17,031 11 17,042 Operating earnings 3,446 (562 ) 2,884 Other income 500 — 500 Interest expense (258 ) — (258 ) Earnings before income taxes 3,688 (562 ) 3,126 Income tax expense 803 (138 ) 665 Net earnings 2,885 (424 ) 2,461 Net earnings attributable to the noncontrolling interest 86 — 86 Net earnings attributable to Kewaunee Scientific Corporation $ 2,799 $ (424 ) $ 2,375 Basic Earnings Per Share $ 1.02 $ (0.15 ) $ 0.87 Diluted Earnings Per Share $ 1.00 $ (0.15 ) $ 0.85 The following table summarizes the impact of adopting ASC 606 on the Company’s condensed consolidated balance sheet: January 31, 2019 ($ in thousands) As Reported Adjustments Balance Without Adoption of ASC 606 Assets Cash and cash equivalents $ 10,771 $ — $ 10,771 Restricted cash 606 — 606 Receivables, less allowances 27,929 (3,304 ) 24,625 Inventories 16,672 3,106 19,778 Prepaid expenses and other assets 3,778 — 3,778 Total Current Assets 59,756 (198 ) 59,558 Net property, plant and equipment 15,202 — 15,202 Other assets 4,604 — 4,604 Total Assets $ 79,562 $ (198 ) $ 79,364 Liabilities and Stockholders’ Equity Short-term borrowings and interest rate swaps $ 5,118 $ — $ 5,118 Current portion of long-term debt and lease obligations 1,184 — 1,184 Accounts payable 11,106 (4 ) 11,102 Deferred revenue 1,450 661 2,111 Other current liabilities 4,848 (214 ) 4,634 Total Current Liabilities 23,706 443 24,149 Other non-current liabilities 6,345 — 6,345 Total Liabilities 30,051 443 30,494 Noncontrolling interest 521 — 521 Total Kewaunee Scientific Corporation Stockholders’ Equity 48,990 (641 ) 48,349 Total Stockholders’ Equity 49,511 (641 ) 48,870 Total Liabilities and Stockholders’ Equity $ 79,562 $ (198 ) $ 79,364

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Jan. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments The Company records derivatives on the condensed consolidated balance sheets at fair value and establishes criteria for designation and effectiveness of hedging relationships. The nature of the Company’s business activities involves the management of various financial and market risks, including those related to changes in interest rates. The Company does not enter into derivative instruments for speculative purposes. In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $3,450,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.875% for the period beginning May 1, 2013 and ending August 1, 2017 . In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $2,600,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 4.37% for the period beginning August 1, 2017 and ending May 1, 2020 . In May 2013, the Company entered into an interest rate swap agreement whereby the interest rate payable by the Company on $1,218,000 of outstanding long-term debt was effectively converted to a fixed interest rate of 3.07% for the period beginning November 3, 2014 and ending May 1, 2020 . The Company entered into these interest rate swap arrangements to mitigate future interest rate risk associated with its long-term debt and has designated these as cash flow hedges.

Earnings Per Share

Earnings Per Share	9 Months Ended
	Jan. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Basic earnings per share is based on the weighted average number of common shares outstanding during the three and nine month periods. Diluted earnings per share reflects the assumed exercise and conversion of restricted stock units and outstanding stock options under the Company’s Omnibus Incentive Plan, except when such awards have an anti-dilutive effect. There were no antidilutive awards outstanding at January 31, 2019 and January 31, 2018 .

Inventories

Inventories	9 Months Ended
	Jan. 31, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Effective August 1, 2018, the Company elected to change its method of inventory accounting to the FIFO method from the LIFO link-chain dollar-value method for its Domestic segment inventories. The Company believes that the FIFO method is preferable as it results in increased uniformity across the Company’s operations with respect to the inventory valuation method, as the Company’s International subsidiaries use the FIFO method. The Company also believes that the change to FIFO will improve financial reporting by better reflecting the current value of inventory on the condensed consolidated balance sheets, by more closely aligning the flow of physical inventory with the accounting for the inventory, providing better matching of revenues and expenses. The Company applied this change in method of inventory accounting by retrospectively adjusting all prior period financial statements and footnote information presented herein as necessary. Inventories consisted of the following (in thousands): January 31, As Adjusted Finished products $ 3,591 $ 4,987 Work in process 1,804 2,393 Raw materials 11,277 11,169 $ 16,672 $ 18,549 The Company’s International subsidiaries’ inventories were $1,410,000 at January 31, 2019 and $1,908,000 , at April 30, 2018 , measured using the FIFO method at the lower of cost and net realizable value and are included in the above tables. Certain amounts in the Company’s condensed consolidated balance sheet as of April 30, 2018 were adjusted as follows (in thousands): April 30, 2018 As Originally Reported Adjustments As Adjusted Inventories $ 17,662 $ 887 $ 18,549 Total Current Assets 63,504 887 64,391 Deferred Income Taxes 2,031 (162 ) 1,869 Total Assets 84,358 725 85,083 Other Accrued Expenses 2,062 54 2,116 Total Current Liabilities 27,562 54 27,616 Total Liabilities 36,837 54 36,891 Retained Earnings 43,165 671 43,836 Total Kewaunee Scientific Corporation Stockholders’ Equity 47,059 671 47,730 Total Stockholders’ Equity 47,521 671 48,192 Total Liabilities and Stockholders’ Equity $ 84,358 $ 725 $ 85,083 Certain amounts in the Company’s condensed consolidated statement of operations for the three and nine months ended January 31, 2018 under the FIFO method would have been as follows (in thousands, except per share amounts): Three Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Cost of products sold $ 29,836 $ (45 ) $ 29,791 Income tax expense 1,566 15 1,581 Net earnings 918 30 948 Net earnings attributable to Kewaunee Scientific Corporation $ 883 $ 30 $ 913 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 0.32 $ 0.01 $ 0.33 Diluted $ 0.31 $ 0.01 $ 0.32 Nine Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Cost of products sold $ 90,456 $ (45 ) $ 90,411 Income tax expense 3,149 15 3,164 Net earnings 3,875 30 3,905 Net earnings attributable to Kewaunee Scientific Corporation $ 3,755 $ 30 $ 3,785 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.38 $ 0.01 $ 1.39 Diluted $ 1.35 $ 0.01 $ 1.36 Certain amounts in the Company’s condensed consolidated statement of cash flows as of January 31, 2018 would have been as follows under the FIFO method (in thousands): Nine Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Net earnings $ 3,875 $ 30 $ 3,905 Decrease in inventories (2,745 ) (45 ) (2,790 ) Increase in accounts payable and other accrued expenses 2,020 15 2,035 Net cash used in operating activities $ (645 ) $ — $ (645 ) Certain amounts in the Company’s condensed consolidated statement of operations for the three and nine months ended January 31, 2019 under the former LIFO method would have been as follows (in thousands, except per share amounts): Three Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Cost of products sold $ 27,142 $ (49 ) $ 27,093 Income tax expense 20 12 32 Net earnings 15 37 52 Net earnings (loss) attributable to Kewaunee Scientific Corporation $ (22 ) $ 37 $ 15 Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders Basic $ (0.01 ) $ 0.01 $ — Diluted $ (0.01 ) $ 0.01 $ — Nine Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Cost of products sold $ 91,325 $ 151 $ 91,476 Income tax expense 803 (37 ) 766 Net earnings 2,885 (114 ) 2,771 Net earnings attributable to Kewaunee Scientific Corporation $ 2,799 $ (114 ) $ 2,685 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.02 $ (0.04 ) $ 0.98 Diluted $ 1.00 $ (0.04 ) $ 0.96 Certain amounts in the Company’s condensed consolidated statement of cash flows as of January 31, 2019 would have been as follows under the former LIFO method (in thousands): Nine Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Net earnings $ 2,885 $ (114 ) $ 2,771 Decrease in inventories 990 151 1,141 Decrease in accounts payable and other accrued expenses (4,879 ) (37 ) (4,916 ) Net cash provided by operating activities $ 4,534 $ — $ 4,534 Certain amounts in the Company’s condensed consolidated balance sheet as of January 31, 2019 would have been as follows under the former LIFO method (in thousands): January 31, 2019 As Reported Under FIFO Adjustment As Computed Under LIFO Inventories $ 16,672 $ (1,038 ) $ 15,634 Total Current Assets 59,756 (1,038 ) 58,718 Deferred Income Taxes 1,676 162 1,838 Total Assets 79,562 (876 ) 78,686 Other Accrued Expenses 2,894 (91 ) 2,803 Total Current Liabilities 23,706 (91 ) 23,615 Total Liabilities 30,051 (91 ) 29,960 Retained Earnings 45,345 (785 ) 44,560 Total Kewaunee Scientific Corporation Stockholders’ Equity 48,990 (785 ) 48,205 Total Stockholders’ Equity 49,511 (785 ) 48,726 Total Liabilities and Stockholders’ Equity $ 79,562 $ (876 ) $ 78,686

Segment Information

Segment Information	9 Months Ended
	Jan. 31, 2019
Segment Reporting [Abstract]
Segment Information	Segment Information The Company’s operations are classified into two business segments: Domestic and International. The Domestic business segment principally designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, worksurfaces, workstations, workbenches, and computer enclosures. The International business segment, which consists of the Company’s foreign subsidiaries, provides products and services, including facility design, detailed engineering, construction, and project management from the planning stage through testing and commissioning of laboratories. Intersegment transactions are recorded at normal profit margins. All intercompany balances and transactions have been eliminated. Certain corporate expenses shown below have not been allocated to the business segments. The following tables provide financial information by business segments for the three and nine months ended January 31, 2019 and 2018 (in thousands): Domestic Operations International Operations Corporate / Eliminations Total Three months ended January 31, 2019 Revenues from external customers $ 25,217 $ 7,155 $ — $ 32,372 Intersegment revenues 612 2,135 (2,747 ) — Earnings (loss) before income taxes $ 60 $ 1,020 $ (1,045 ) $ 35 Three months ended January 31, 2018 Revenues from external customers $ 29,734 $ 8,456 $ — $ 38,190 Intersegment revenues 1,145 1,361 (2,506 ) — Earnings (loss) before income taxes $ 3,004 $ 1,363 $ (1,838 ) $ 2,529 Domestic Operations International Operations Corporate/ Eliminations Total Nine months ended January 31, 2019 Revenues from external customers $ 91,909 $ 19,893 $ — $ 111,802 Intersegment revenues 1,490 3,969 (5,459 ) — Earnings (loss) before income taxes $ 6,005 $ 2,174 $ (4,491 ) $ 3,688 Nine months ended January 31, 2018 Revenues from external customers $ 80,420 $ 33,122 $ — $ 113,542 Intersegment revenues 10,298 3,291 (13,589 ) — Earnings (loss) before income taxes $ 7,765 $ 4,019 $ (4,715 ) $ 7,069

Defined Benefit Pension Plans

Defined Benefit Pension Plans	9 Months Ended
	Jan. 31, 2019
Retirement Benefits [Abstract]
Defined Benefit Pension Plans	Defined Benefit Pension Plans The Company has non-contributory defined benefit pension plans covering substantially all domestic salaried and hourly employees. These plans were amended as of April 30, 2005; no further benefits have been, or will be, earned under the plans, subsequent to the amendment date, and no additional participants will be added to the plans. Company contributions of $1,000,000 were paid to the plans during the nine months ended January 31, 2019 , and the Company does not expect any contributions to be paid to the plans during the remainder of the fiscal year. Contributions of $600,000 were paid to the plans during the nine months ended January 31, 2018 . The Company assumed an expected long-term rate of return of 7.75% for the period ended January 31, 2019 as compared to 7.75% for the period ended January 31, 2018 . Pension expense consisted of the following (in thousands): Three Months Ended January 31, 2019 Three Months Ended January 31, 2018 Service cost $ 0 $ 0 Interest cost 214 219 Expected return on plan assets (362 ) (328 ) Recognition of net loss 221 283 Net periodic pension expense $ 73 $ 174 Nine Months Ended January 31, 2019 Nine Months Ended Service cost $ 0 $ 0 Interest cost 644 657 Expected return on plan assets (1,086 ) (984 ) Recognition of net loss 663 849 Net periodic pension expense $ 221 $ 522

Fair Value of Financial Instrum

Fair Value of Financial Instruments	9 Months Ended
	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	Fair Value of Financial Instruments The Company’s financial instruments consist primarily of cash and equivalents, mutual funds, cash surrender value of life insurance policies, term loans and short-term borrowings. The carrying value of these assets and liabilities approximate their fair value. The following tables summarize the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2019 and April 30, 2018 (in thousands): January 31, 2019 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 2,818 $ — $ 2,818 Cash surrender value of life insurance policies (1) — 65 65 Total $ 2,818 $ 65 $ 2,883 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,256 $ 3,256 April 30, 2018 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 4,050 $ — $ 4,050 Cash surrender value of life insurance policies (1) — 65 65 Total $ 4,050 $ 65 $ 4,115 Financial Liabilities Non-qualified compensation plans (2) $ — $ 4,462 $ 4,462 Interest rate swap derivatives — 5 5 Total $ — $ 4,467 $ 4,467 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants’ account balances and other earned retirement benefits.

Stock Options and Share-based C

Stock Options and Share-based Compensation	9 Months Ended
	Jan. 31, 2019
Equity [Abstract]
Stock Options and Share-based Compensation	Stock Options and Share-based Compensation The Company adopted ASU 2016-9, “Stock Compensation – Improvements to Employee Share-Based Payment Accounting” prospectively effective May 1, 2017. Prior periods were not retrospectively adjusted. The Company elected prospectively to account for forfeitures as they occur rather than apply an estimated rate to share-based compensation expense. Compensation costs related to stock options and other stock awards granted by the Company are charged against operating expenses during their vesting period, under ASC 718, “Compensation – Stock Compensation.” The Company granted 17,769 restricted stock units (“RSUs”) under the 2017 Omnibus Incentive Plan in June 2018. The RSUs include both a service and a performance component, vesting over a three year period. The recognized expense is based upon the vesting period for service criteria and estimated attainment of the performance criteria at the end of the three year period based on the ratio of cumulative days incurred, to total days over the three year period. The Company recorded share-based compensation expense during the three and nine months ended January 31, 2019 of $45,000 and $106,000 , respectively, for this issuance with the remaining estimated share-based compensation expense of $406,000 to be recorded over the remaining three year period.

Income Taxes

Income Taxes	9 Months Ended
	Jan. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”) was signed into law. The 2017 Tax Act includes a broad range of tax reform provisions affecting businesses, including lower corporate tax rates, changes in business deductions, and international tax provisions. In response to the 2017 Tax Act, the Commission staff issued Staff Accounting Bulletin No. 118 (“SAB 118”) to address the application of U.S. GAAP in situations where a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the 2017 Tax Act. SAB 118 provides that the measurement period is complete when a company’s accounting is complete and that the measurement period shall not extend beyond one year from the enactment date. SAB 118 provides guidance for registrants under three scenarios: (i) measurement of certain income tax effects is complete, (ii) measurement of certain income tax effects can be reasonably estimated, and (iii) measurement of certain income tax effects cannot be reasonably estimated. The Company has completed its accounting for the enactment of the 2017 Tax Act in accordance with SAB 118 in the quarter ended January 31, 2019. No material adjustments to income tax expense were recorded in regards to the provisional amounts recorded at April 30, 2018. During the nine months ended January 31, 2019, the Company finalized the accounting policy decision with respect to the new Global Intangible Low-Taxed Income ("GILTI") tax rules and has concluded that GILTI will be treated as a periodic charge in the year in which it arises. Therefore, the Company will not record deferred taxes for the basis associated with GILTI earnings. The Company has included estimated tax expense related to GILTI for current year operations in the forecasted effective tax rate.

Reclassifications

Reclassifications	9 Months Ended
	Jan. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Reclassifications	Reclassifications In connection with the Company's adoption of ASU 2016-18, “Statement of Cash Flows-Restricted Cash,” the Company reclassified certain 2018 amounts in the condensed consolidated statements of cash flows to include restricted cash when reconciling the beginning-of-period and end-of-period cash amounts shown on the statement of cash flows to conform to the current period presentation. To comply with the Commission’s final rule on Disclosure Simplification, the Company’s presentation of the prior period’s condensed consolidated statement of stockholders’ equity has been reclassed to conform to the current period format.

New Accounting Standards

New Accounting Standards	9 Months Ended
	Jan. 31, 2019
Accounting Changes and Error Corrections [Abstract]
New Accounting Standards	New Accounting Standards In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update 2014-09, “Revenue from Contracts with Customers”. This update outlined a new comprehensive revenue recognition model that supersedes most current revenue recognition guidance and required companies to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflected the consideration to which the entity expected to be entitled in exchange for those goods or services. The Company adopted this standard effective May 1, 2018. See Note B for a discussion of the impact of the adoption of this standard. In February 2016, the FASB issued ASU 2016-2, “Leases.” This guidance establishes a right-of-use (ROU) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. The Company will adopt this standard in fiscal year 2020. While the Company will be required to record a ROU asset and lease liability on the balance sheet related to this standard, the Company has determined that the adoption of this standard will not have a significant impact on the Company’s consolidated financial position or results of operations. In August 2016, the FASB issued ASU 2016-15, “Cash Flow Classification of Certain Cash Receipts and Cash Payments,” which clarifies guidance on classification of certain transactions in the statement of cash flows, including classification of debt prepayments, debt extinguishment costs and contingent consideration payments after a business combination. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations. In November 2016, the FASB issued ASU 2016-18, “Statement of Cash Flows – Restricted Cash,” which requires that the statement of cash flows reconcile the change during the period in total cash, cash equivalents and restricted cash. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations. In March 2017, the FASB issued ASU 2017-07, “Compensation – Retirement Benefits – Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Cost,” which requires that the service cost component of net periodic pension cost is presented in the same line as other compensation costs arising from services rendered by the respective employees during the year. The other components of net periodic pension cost are required to be presented in the income statement separately from the service cost component and outside of earnings from operations. This guidance allows for the service cost component to be eligible for capitalization when applicable. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations. In May 2017, the FASB issued ASU 2017-09, “Compensation – Stock Compensation – Scope of Modification Accounting.” This guidance was issued in an effort to reduce diversity in practice as it relates to applying modification accounting for changes to the terms and conditions of share-based payment awards. This guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017, with early adoption permitted. The Company adopted this standard effective May 1, 2018. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations. In August 2018, the Commission adopted the final rule under Commission Release No. 33-10532, “Disclosure Update and Simplification,” amending certain disclosure requirements that were redundant, duplicative, overlapping, outdated or superseded. In addition, the amendments expanded the disclosure requirements relating to the analysis of stockholders’ equity for interim financial statements. Under the amendments, an analysis of changes in each caption of stockholders’ equity presented in the balance sheet must be provided in a note or separate statement. The analysis should present a reconciliation of the beginning balance to the ending balance of each period for which a statement of income is required to be filed. This final rule became effective on November 5, 2018. The Company adopted this final rule effective for the second quarter of fiscal 2019. The adoption of this standard did not have a significant impact on the Company’s consolidated financial position or results of operations.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	9 Months Ended
	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Disaggregation of Revenue	A summary of net sales transferred to customers at a point in time and over time for the three and nine months ended January 31, 2019 is as follows (in thousands): Three Months Ended January 31, 2019 Domestic International Total Over Time $ 24,414 $ 7,155 $ 31,569 Point in Time 803 — 803 $ 25,217 $ 7,155 $ 32,372 Nine Months Ended January 31, 2019 Domestic International Total Over Time $ 86,973 $ 19,893 $ 106,866 Point in Time 4,936 — 4,936 $ 91,909 $ 19,893 $ 111,802
Schedule of Prospective Adoption of New Accounting Pronouncements	The following tables summarize the impact of adopting ASC 606 on the condensed consolidated statements of operations: Three Months Ended January 31, 2019 ($ in thousands, except per share amounts) As Reported Adjustments Balance Without Adoption of ASC 606 Net sales $ 32,372 $ (1,668 ) $ 30,704 Costs of products sold 27,142 (1,519 ) 25,623 Gross profit 5,230 (149 ) 5,081 Operating expenses 5,305 6 5,311 Operating loss (75 ) (155 ) (230 ) Other income 186 — 186 Interest expense (76 ) — (76 ) Earnings (loss) before income taxes 35 (155 ) (120 ) Income tax expense (benefit) 20 (46 ) (26 ) Net earnings (loss) 15 (109 ) (94 ) Net earnings attributable to the noncontrolling interest 37 — 37 Net earnings (loss) attributable to Kewaunee Scientific Corporation $ (22 ) $ (109 ) $ (131 ) Basic Loss Per Share $ (0.01 ) $ (0.04 ) $ (0.05 ) Diluted Loss Per Share $ (0.01 ) $ (0.04 ) $ (0.05 ) Nine Months Ended January 31, 2019 ($ in thousands, except per share amounts) As Reported Adjustments Balance Without Adoption of ASC 606 Net sales $ 111,802 $ (1,720 ) $ 110,082 Costs of products sold 91,325 (1,169 ) 90,156 Gross profit 20,477 (551 ) 19,926 Operating expenses 17,031 11 17,042 Operating earnings 3,446 (562 ) 2,884 Other income 500 — 500 Interest expense (258 ) — (258 ) Earnings before income taxes 3,688 (562 ) 3,126 Income tax expense 803 (138 ) 665 Net earnings 2,885 (424 ) 2,461 Net earnings attributable to the noncontrolling interest 86 — 86 Net earnings attributable to Kewaunee Scientific Corporation $ 2,799 $ (424 ) $ 2,375 Basic Earnings Per Share $ 1.02 $ (0.15 ) $ 0.87 Diluted Earnings Per Share $ 1.00 $ (0.15 ) $ 0.85 The following table summarizes the impact of adopting ASC 606 on the Company’s condensed consolidated balance sheet: January 31, 2019 ($ in thousands) As Reported Adjustments Balance Without Adoption of ASC 606 Assets Cash and cash equivalents $ 10,771 $ — $ 10,771 Restricted cash 606 — 606 Receivables, less allowances 27,929 (3,304 ) 24,625 Inventories 16,672 3,106 19,778 Prepaid expenses and other assets 3,778 — 3,778 Total Current Assets 59,756 (198 ) 59,558 Net property, plant and equipment 15,202 — 15,202 Other assets 4,604 — 4,604 Total Assets $ 79,562 $ (198 ) $ 79,364 Liabilities and Stockholders’ Equity Short-term borrowings and interest rate swaps $ 5,118 $ — $ 5,118 Current portion of long-term debt and lease obligations 1,184 — 1,184 Accounts payable 11,106 (4 ) 11,102 Deferred revenue 1,450 661 2,111 Other current liabilities 4,848 (214 ) 4,634 Total Current Liabilities 23,706 443 24,149 Other non-current liabilities 6,345 — 6,345 Total Liabilities 30,051 443 30,494 Noncontrolling interest 521 — 521 Total Kewaunee Scientific Corporation Stockholders’ Equity 48,990 (641 ) 48,349 Total Stockholders’ Equity 49,511 (641 ) 48,870 Total Liabilities and Stockholders’ Equity $ 79,562 $ (198 ) $ 79,364 Certain amounts in the Company’s condensed consolidated balance sheet as of April 30, 2018 were adjusted as follows (in thousands): April 30, 2018 As Originally Reported Adjustments As Adjusted Inventories $ 17,662 $ 887 $ 18,549 Total Current Assets 63,504 887 64,391 Deferred Income Taxes 2,031 (162 ) 1,869 Total Assets 84,358 725 85,083 Other Accrued Expenses 2,062 54 2,116 Total Current Liabilities 27,562 54 27,616 Total Liabilities 36,837 54 36,891 Retained Earnings 43,165 671 43,836 Total Kewaunee Scientific Corporation Stockholders’ Equity 47,059 671 47,730 Total Stockholders’ Equity 47,521 671 48,192 Total Liabilities and Stockholders’ Equity $ 84,358 $ 725 $ 85,083 Certain amounts in the Company’s condensed consolidated statement of operations for the three and nine months ended January 31, 2018 under the FIFO method would have been as follows (in thousands, except per share amounts): Three Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Cost of products sold $ 29,836 $ (45 ) $ 29,791 Income tax expense 1,566 15 1,581 Net earnings 918 30 948 Net earnings attributable to Kewaunee Scientific Corporation $ 883 $ 30 $ 913 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 0.32 $ 0.01 $ 0.33 Diluted $ 0.31 $ 0.01 $ 0.32 Nine Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Cost of products sold $ 90,456 $ (45 ) $ 90,411 Income tax expense 3,149 15 3,164 Net earnings 3,875 30 3,905 Net earnings attributable to Kewaunee Scientific Corporation $ 3,755 $ 30 $ 3,785 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.38 $ 0.01 $ 1.39 Diluted $ 1.35 $ 0.01 $ 1.36 Certain amounts in the Company’s condensed consolidated statement of cash flows as of January 31, 2018 would have been as follows under the FIFO method (in thousands): Nine Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Net earnings $ 3,875 $ 30 $ 3,905 Decrease in inventories (2,745 ) (45 ) (2,790 ) Increase in accounts payable and other accrued expenses 2,020 15 2,035 Net cash used in operating activities $ (645 ) $ — $ (645 ) Certain amounts in the Company’s condensed consolidated statement of operations for the three and nine months ended January 31, 2019 under the former LIFO method would have been as follows (in thousands, except per share amounts): Three Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Cost of products sold $ 27,142 $ (49 ) $ 27,093 Income tax expense 20 12 32 Net earnings 15 37 52 Net earnings (loss) attributable to Kewaunee Scientific Corporation $ (22 ) $ 37 $ 15 Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders Basic $ (0.01 ) $ 0.01 $ — Diluted $ (0.01 ) $ 0.01 $ — Nine Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Cost of products sold $ 91,325 $ 151 $ 91,476 Income tax expense 803 (37 ) 766 Net earnings 2,885 (114 ) 2,771 Net earnings attributable to Kewaunee Scientific Corporation $ 2,799 $ (114 ) $ 2,685 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.02 $ (0.04 ) $ 0.98 Diluted $ 1.00 $ (0.04 ) $ 0.96 Certain amounts in the Company’s condensed consolidated statement of cash flows as of January 31, 2019 would have been as follows under the former LIFO method (in thousands): Nine Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Net earnings $ 2,885 $ (114 ) $ 2,771 Decrease in inventories 990 151 1,141 Decrease in accounts payable and other accrued expenses (4,879 ) (37 ) (4,916 ) Net cash provided by operating activities $ 4,534 $ — $ 4,534 Certain amounts in the Company’s condensed consolidated balance sheet as of January 31, 2019 would have been as follows under the former LIFO method (in thousands): January 31, 2019 As Reported Under FIFO Adjustment As Computed Under LIFO Inventories $ 16,672 $ (1,038 ) $ 15,634 Total Current Assets 59,756 (1,038 ) 58,718 Deferred Income Taxes 1,676 162 1,838 Total Assets 79,562 (876 ) 78,686 Other Accrued Expenses 2,894 (91 ) 2,803 Total Current Liabilities 23,706 (91 ) 23,615 Total Liabilities 30,051 (91 ) 29,960 Retained Earnings 45,345 (785 ) 44,560 Total Kewaunee Scientific Corporation Stockholders’ Equity 48,990 (785 ) 48,205 Total Stockholders’ Equity 49,511 (785 ) 48,726 Total Liabilities and Stockholders’ Equity $ 79,562 $ (876 ) $ 78,686

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Jan. 31, 2019
Inventory Disclosure [Abstract]
Summary of Inventories	January 31, As Adjusted Finished products $ 3,591 $ 4,987 Work in process 1,804 2,393 Raw materials 11,277 11,169 $ 16,672 $ 18,549
Summary of Impact of Adoption of New Accounting Principle in Financial Statements	The following tables summarize the impact of adopting ASC 606 on the condensed consolidated statements of operations: Three Months Ended January 31, 2019 ($ in thousands, except per share amounts) As Reported Adjustments Balance Without Adoption of ASC 606 Net sales $ 32,372 $ (1,668 ) $ 30,704 Costs of products sold 27,142 (1,519 ) 25,623 Gross profit 5,230 (149 ) 5,081 Operating expenses 5,305 6 5,311 Operating loss (75 ) (155 ) (230 ) Other income 186 — 186 Interest expense (76 ) — (76 ) Earnings (loss) before income taxes 35 (155 ) (120 ) Income tax expense (benefit) 20 (46 ) (26 ) Net earnings (loss) 15 (109 ) (94 ) Net earnings attributable to the noncontrolling interest 37 — 37 Net earnings (loss) attributable to Kewaunee Scientific Corporation $ (22 ) $ (109 ) $ (131 ) Basic Loss Per Share $ (0.01 ) $ (0.04 ) $ (0.05 ) Diluted Loss Per Share $ (0.01 ) $ (0.04 ) $ (0.05 ) Nine Months Ended January 31, 2019 ($ in thousands, except per share amounts) As Reported Adjustments Balance Without Adoption of ASC 606 Net sales $ 111,802 $ (1,720 ) $ 110,082 Costs of products sold 91,325 (1,169 ) 90,156 Gross profit 20,477 (551 ) 19,926 Operating expenses 17,031 11 17,042 Operating earnings 3,446 (562 ) 2,884 Other income 500 — 500 Interest expense (258 ) — (258 ) Earnings before income taxes 3,688 (562 ) 3,126 Income tax expense 803 (138 ) 665 Net earnings 2,885 (424 ) 2,461 Net earnings attributable to the noncontrolling interest 86 — 86 Net earnings attributable to Kewaunee Scientific Corporation $ 2,799 $ (424 ) $ 2,375 Basic Earnings Per Share $ 1.02 $ (0.15 ) $ 0.87 Diluted Earnings Per Share $ 1.00 $ (0.15 ) $ 0.85 The following table summarizes the impact of adopting ASC 606 on the Company’s condensed consolidated balance sheet: January 31, 2019 ($ in thousands) As Reported Adjustments Balance Without Adoption of ASC 606 Assets Cash and cash equivalents $ 10,771 $ — $ 10,771 Restricted cash 606 — 606 Receivables, less allowances 27,929 (3,304 ) 24,625 Inventories 16,672 3,106 19,778 Prepaid expenses and other assets 3,778 — 3,778 Total Current Assets 59,756 (198 ) 59,558 Net property, plant and equipment 15,202 — 15,202 Other assets 4,604 — 4,604 Total Assets $ 79,562 $ (198 ) $ 79,364 Liabilities and Stockholders’ Equity Short-term borrowings and interest rate swaps $ 5,118 $ — $ 5,118 Current portion of long-term debt and lease obligations 1,184 — 1,184 Accounts payable 11,106 (4 ) 11,102 Deferred revenue 1,450 661 2,111 Other current liabilities 4,848 (214 ) 4,634 Total Current Liabilities 23,706 443 24,149 Other non-current liabilities 6,345 — 6,345 Total Liabilities 30,051 443 30,494 Noncontrolling interest 521 — 521 Total Kewaunee Scientific Corporation Stockholders’ Equity 48,990 (641 ) 48,349 Total Stockholders’ Equity 49,511 (641 ) 48,870 Total Liabilities and Stockholders’ Equity $ 79,562 $ (198 ) $ 79,364 Certain amounts in the Company’s condensed consolidated balance sheet as of April 30, 2018 were adjusted as follows (in thousands): April 30, 2018 As Originally Reported Adjustments As Adjusted Inventories $ 17,662 $ 887 $ 18,549 Total Current Assets 63,504 887 64,391 Deferred Income Taxes 2,031 (162 ) 1,869 Total Assets 84,358 725 85,083 Other Accrued Expenses 2,062 54 2,116 Total Current Liabilities 27,562 54 27,616 Total Liabilities 36,837 54 36,891 Retained Earnings 43,165 671 43,836 Total Kewaunee Scientific Corporation Stockholders’ Equity 47,059 671 47,730 Total Stockholders’ Equity 47,521 671 48,192 Total Liabilities and Stockholders’ Equity $ 84,358 $ 725 $ 85,083 Certain amounts in the Company’s condensed consolidated statement of operations for the three and nine months ended January 31, 2018 under the FIFO method would have been as follows (in thousands, except per share amounts): Three Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Cost of products sold $ 29,836 $ (45 ) $ 29,791 Income tax expense 1,566 15 1,581 Net earnings 918 30 948 Net earnings attributable to Kewaunee Scientific Corporation $ 883 $ 30 $ 913 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 0.32 $ 0.01 $ 0.33 Diluted $ 0.31 $ 0.01 $ 0.32 Nine Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Cost of products sold $ 90,456 $ (45 ) $ 90,411 Income tax expense 3,149 15 3,164 Net earnings 3,875 30 3,905 Net earnings attributable to Kewaunee Scientific Corporation $ 3,755 $ 30 $ 3,785 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.38 $ 0.01 $ 1.39 Diluted $ 1.35 $ 0.01 $ 1.36 Certain amounts in the Company’s condensed consolidated statement of cash flows as of January 31, 2018 would have been as follows under the FIFO method (in thousands): Nine Months Ended January 31, 2018 As Reported Under LIFO Adjustments As Adjusted Under FIFO Net earnings $ 3,875 $ 30 $ 3,905 Decrease in inventories (2,745 ) (45 ) (2,790 ) Increase in accounts payable and other accrued expenses 2,020 15 2,035 Net cash used in operating activities $ (645 ) $ — $ (645 ) Certain amounts in the Company’s condensed consolidated statement of operations for the three and nine months ended January 31, 2019 under the former LIFO method would have been as follows (in thousands, except per share amounts): Three Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Cost of products sold $ 27,142 $ (49 ) $ 27,093 Income tax expense 20 12 32 Net earnings 15 37 52 Net earnings (loss) attributable to Kewaunee Scientific Corporation $ (22 ) $ 37 $ 15 Net earnings (loss) per share attributable to Kewaunee Scientific Corporation stockholders Basic $ (0.01 ) $ 0.01 $ — Diluted $ (0.01 ) $ 0.01 $ — Nine Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Cost of products sold $ 91,325 $ 151 $ 91,476 Income tax expense 803 (37 ) 766 Net earnings 2,885 (114 ) 2,771 Net earnings attributable to Kewaunee Scientific Corporation $ 2,799 $ (114 ) $ 2,685 Net earnings per share attributable to Kewaunee Scientific Corporation stockholders Basic $ 1.02 $ (0.04 ) $ 0.98 Diluted $ 1.00 $ (0.04 ) $ 0.96 Certain amounts in the Company’s condensed consolidated statement of cash flows as of January 31, 2019 would have been as follows under the former LIFO method (in thousands): Nine Months Ended January 31, 2019 As Reported Under FIFO Adjustments As Computed Under LIFO Net earnings $ 2,885 $ (114 ) $ 2,771 Decrease in inventories 990 151 1,141 Decrease in accounts payable and other accrued expenses (4,879 ) (37 ) (4,916 ) Net cash provided by operating activities $ 4,534 $ — $ 4,534 Certain amounts in the Company’s condensed consolidated balance sheet as of January 31, 2019 would have been as follows under the former LIFO method (in thousands): January 31, 2019 As Reported Under FIFO Adjustment As Computed Under LIFO Inventories $ 16,672 $ (1,038 ) $ 15,634 Total Current Assets 59,756 (1,038 ) 58,718 Deferred Income Taxes 1,676 162 1,838 Total Assets 79,562 (876 ) 78,686 Other Accrued Expenses 2,894 (91 ) 2,803 Total Current Liabilities 23,706 (91 ) 23,615 Total Liabilities 30,051 (91 ) 29,960 Retained Earnings 45,345 (785 ) 44,560 Total Kewaunee Scientific Corporation Stockholders’ Equity 48,990 (785 ) 48,205 Total Stockholders’ Equity 49,511 (785 ) 48,726 Total Liabilities and Stockholders’ Equity $ 79,562 $ (876 ) $ 78,686

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Jan. 31, 2019
Segment Reporting [Abstract]
Segment Information	The following tables provide financial information by business segments for the three and nine months ended January 31, 2019 and 2018 (in thousands): Domestic Operations International Operations Corporate / Eliminations Total Three months ended January 31, 2019 Revenues from external customers $ 25,217 $ 7,155 $ — $ 32,372 Intersegment revenues 612 2,135 (2,747 ) — Earnings (loss) before income taxes $ 60 $ 1,020 $ (1,045 ) $ 35 Three months ended January 31, 2018 Revenues from external customers $ 29,734 $ 8,456 $ — $ 38,190 Intersegment revenues 1,145 1,361 (2,506 ) — Earnings (loss) before income taxes $ 3,004 $ 1,363 $ (1,838 ) $ 2,529 Domestic Operations International Operations Corporate/ Eliminations Total Nine months ended January 31, 2019 Revenues from external customers $ 91,909 $ 19,893 $ — $ 111,802 Intersegment revenues 1,490 3,969 (5,459 ) — Earnings (loss) before income taxes $ 6,005 $ 2,174 $ (4,491 ) $ 3,688 Nine months ended January 31, 2018 Revenues from external customers $ 80,420 $ 33,122 $ — $ 113,542 Intersegment revenues 10,298 3,291 (13,589 ) — Earnings (loss) before income taxes $ 7,765 $ 4,019 $ (4,715 ) $ 7,069

Defined Benefit Pension Plans (

Defined Benefit Pension Plans (Tables)	9 Months Ended
	Jan. 31, 2019
Retirement Benefits [Abstract]
Pension Expenses	Pension expense consisted of the following (in thousands): Three Months Ended January 31, 2019 Three Months Ended January 31, 2018 Service cost $ 0 $ 0 Interest cost 214 219 Expected return on plan assets (362 ) (328 ) Recognition of net loss 221 283 Net periodic pension expense $ 73 $ 174 Nine Months Ended January 31, 2019 Nine Months Ended Service cost $ 0 $ 0 Interest cost 644 657 Expected return on plan assets (1,086 ) (984 ) Recognition of net loss 663 849 Net periodic pension expense $ 221 $ 522

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	9 Months Ended
	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis	The following tables summarize the Company’s fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis as of January 31, 2019 and April 30, 2018 (in thousands): January 31, 2019 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 2,818 $ — $ 2,818 Cash surrender value of life insurance policies (1) — 65 65 Total $ 2,818 $ 65 $ 2,883 Financial Liabilities Non-qualified compensation plans (2) $ — $ 3,256 $ 3,256 April 30, 2018 Financial Assets Level 1 Level 2 Total Trading securities held in non-qualified compensation plans (1) $ 4,050 $ — $ 4,050 Cash surrender value of life insurance policies (1) — 65 65 Total $ 4,050 $ 65 $ 4,115 Financial Liabilities Non-qualified compensation plans (2) $ — $ 4,462 $ 4,462 Interest rate swap derivatives — 5 5 Total $ — $ 4,467 $ 4,467 (1) The Company maintains two non-qualified compensation plans which include investment assets in a rabbi trust. These assets consist of marketable securities, which are valued using quoted market prices multiplied by the number of shares owned, and life insurance policies, which are valued at their cash surrender value. (2) Plan liabilities are equal to the individual participants’ account balances and other earned retirement benefits.

Revenue Recognition - Summary o

Revenue Recognition - Summary of Net Sales Transferred to Customers at a Point in Time and Over Time (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	$ 32,372	$ 38,190	$ 111,802	$ 113,542
Over Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	31,569		106,866
Point in Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	803		4,936
Domestic
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	25,217		91,909
Domestic | Over Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	24,414		86,973
Domestic | Point in Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	803		4,936
International
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	7,155		19,893
International | Over Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	7,155		19,893
International | Point in Time
Disaggregation of Revenue [Line Items]
Net sales transferred to customers	$ 0		$ 0

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended	12 Months Ended
	Jan. 31, 2019	Jan. 31, 2019	Apr. 30, 2018	May 01, 2018
Revenue Recognition [Line Items]
Contract assets and liabilities	$ 1,450	$ 1,450	$ 1,884
Contract liability recognized as revenue percentage	14.00%	95.00%
ASU 2014-09
Revenue Recognition [Line Items]
Cumulative effect adjustment to increase retained earnings				$ 217
Fiscal Year 2019
Revenue Recognition [Line Items]
Contract liability recognized as revenue percentage			100.00%

Revenue Recognition - Summary_2

Revenue Recognition - Summary of Impact of Adopting ASC 606 on Condensed Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Jan. 31, 2018	Oct. 31, 2017	Jul. 31, 2017	Jan. 31, 2019	Jan. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 32,372			$ 38,190			$ 111,802	$ 113,542
Costs of products sold	27,142			29,791			91,325	90,411
Gross profit	5,230			8,399			20,477	23,131
Operating expenses	5,305			5,971			17,031	16,360
Operating earnings (loss)	(75)			2,428			3,446	6,771
Other income	186			179			500	524
Interest expense	(76)			(78)			(258)	(226)
Earnings before income taxes	35			2,529			3,688	7,069
Income tax expense (benefit)	20			1,581			803	3,164
Net earnings	15			948			2,885	3,905
Net earnings attributable to the noncontrolling interest	37			35			86	120
Net earnings (loss) attributable to Kewaunee Scientific Corporation	$ (22)	$ 1,414	$ 1,407	$ 913	$ 1,724	$ 1,148	$ 2,799	$ 3,785
Basic Loss Per Share (in dollars per share)	$ (0.01)			$ 0.33			$ 1.02	$ 1.39
Diluted Loss Per Share (in dollars per share)	$ (0.01)			$ 0.32			$ 1	$ 1.36
Balance Without Adoption of ASC 606
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ 30,704						$ 110,082
Costs of products sold	25,623						90,156
Gross profit	5,081						19,926
Operating expenses	5,311						17,042
Operating earnings (loss)	(230)						2,884
Other income	186						500
Interest expense	(76)						(258)
Earnings before income taxes	(120)						3,126
Income tax expense (benefit)	(26)						665
Net earnings	(94)						2,461
Net earnings attributable to the noncontrolling interest	37						86
Net earnings (loss) attributable to Kewaunee Scientific Corporation	$ (131)						$ 2,375
Basic Loss Per Share (in dollars per share)	$ (0.05)						$ 0.87
Diluted Loss Per Share (in dollars per share)	$ (0.05)						$ 0.85
ASU 2014-09 | Adjustments
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net sales	$ (1,668)						$ (1,720)
Costs of products sold	(1,519)						(1,169)
Gross profit	(149)						(551)
Operating expenses	6						11
Operating earnings (loss)	(155)						(562)
Other income	0						0
Interest expense	0						0
Earnings before income taxes	(155)						(562)
Income tax expense (benefit)	(46)						(138)
Net earnings	(109)						(424)
Net earnings attributable to the noncontrolling interest	0						0
Net earnings (loss) attributable to Kewaunee Scientific Corporation	$ (109)						$ (424)
Basic Loss Per Share (in dollars per share)	$ (0.04)						$ (0.15)
Diluted Loss Per Share (in dollars per share)	$ (0.04)						$ (0.15)

Revenue Recognition - Summary_3

Revenue Recognition - Summary of Impact of Adopting ASC 606 on Company's Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Oct. 31, 2017	Jul. 31, 2017	Apr. 30, 2017
Assets
Cash and cash equivalents	$ 10,771			$ 9,716
Restricted cash	606			1,242
Receivables, less allowances	27,929			32,660
Inventories	16,672			18,549
Prepaid expenses and other assets	3,778			2,224
Total Current Assets	59,756			64,391
Net property, plant and equipment	15,202			14,661
Other assets	4,604			6,031
Total Assets	79,562			85,083
Liabilities and Stockholders’ Equity
Short-term borrowings and interest rate swaps	5,118			3,885
Current portion of long-term debt and lease obligations	1,184			1,167
Accounts payable	11,106			14,754
Deferred revenue	1,450
Other current liabilities	4,848
Total Current Liabilities	23,706			27,616
Other non-current liabilities	6,345
Total Liabilities	30,051			36,891
Noncontrolling interest	521			462
Total Kewaunee Scientific Corporation Stockholders’ Equity	48,990	$ 48,920	$ 48,611	47,730	$ 46,278	$ 45,515	$ 44,347	$ 43,461
Total Stockholders’ Equity	49,511			48,192
Total Liabilities and Stockholders’ Equity	79,562			$ 85,083
Balance Without Adoption of ASC 606
Assets
Cash and cash equivalents	10,771
Restricted cash	606
Receivables, less allowances	24,625
Inventories	19,778
Prepaid expenses and other assets	3,778
Total Current Assets	59,558
Net property, plant and equipment	15,202
Other assets	4,604
Total Assets	79,364
Liabilities and Stockholders’ Equity
Short-term borrowings and interest rate swaps	5,118
Current portion of long-term debt and lease obligations	1,184
Accounts payable	11,102
Deferred revenue	2,111
Other current liabilities	4,634
Total Current Liabilities	24,149
Other non-current liabilities	6,345
Total Liabilities	30,494
Noncontrolling interest	521
Total Kewaunee Scientific Corporation Stockholders’ Equity	48,349
Total Stockholders’ Equity	48,870
Total Liabilities and Stockholders’ Equity	79,364
ASU 2014-09 | Adjustments
Assets
Cash and cash equivalents	0
Restricted cash	0
Receivables, less allowances	(3,304)
Inventories	3,106
Prepaid expenses and other assets	0
Total Current Assets	(198)
Net property, plant and equipment	0
Other assets	0
Total Assets	(198)
Liabilities and Stockholders’ Equity
Short-term borrowings and interest rate swaps	0
Current portion of long-term debt and lease obligations	0
Accounts payable	(4)
Deferred revenue	661
Other current liabilities	(214)
Total Current Liabilities	443
Other non-current liabilities	0
Total Liabilities	443
Noncontrolling interest	0
Total Kewaunee Scientific Corporation Stockholders’ Equity	(641)
Total Stockholders’ Equity	(641)
Total Liabilities and Stockholders’ Equity	$ (198)

Derivative Financial Instrume_2

Derivative Financial Instruments - Additional Information (Detail) - USD ($)	9 Months Ended
	Jan. 31, 2019	May 31, 2013
May 1, 2013 to August 1, 2017
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Outstanding advances under the long-term debt		$ 3,450,000
Interest rate swap, conversion rate	4.875%
Interest rate swap, beginning date of conversion	May 1, 2013
Interest rate swap, ending date of conversion	Aug. 1, 2017
August 1, 2017 to May 1, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Outstanding advances under the long-term debt		2,600,000
Interest rate swap, conversion rate	4.37%
Interest rate swap, beginning date of conversion	Aug. 1, 2017
Interest rate swap, ending date of conversion	May 1, 2020
November 3, 2014 to May 1, 2020
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Outstanding advances under the long-term debt		$ 1,218,000
Interest rate swap, conversion rate	3.07%
Interest rate swap, beginning date of conversion	Nov. 3, 2014
Interest rate swap, ending date of conversion	May 1, 2020

Earnings Per Share - Additional

Earnings Per Share - Additional Information (Detail) - shares	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Earnings Per Share [Abstract]
Anti-dilutive options exclude from computation of earning per share	0	0

Inventories - Summary of Invent

Inventories - Summary of Inventories (Detail) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Inventory [Line Items]
Finished products		$ 4,987
Work in process		2,393
Raw materials		11,169
Total inventories	$ 16,672	18,549
As Adjusted Under FIFO
Inventory [Line Items]
Finished products	3,591
Work in process	1,804
Raw materials	11,277
Total inventories	$ 16,672	$ 17,662

Inventories - Additional Inform

Inventories - Additional Information (Detail) - USD ($)	Jan. 31, 2019	Apr. 30, 2018
International Subsidiaries
Inventory [Line Items]
Inventories measured using FIFO method	$ 1,410,000	$ 1,908,000

Inventories - Schedule of Impac

Inventories - Schedule of Impact on the Company's Condensed Consolidated Balance Sheets (Detail) - USD ($) $ in Thousands	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Apr. 30, 2018	Jan. 31, 2018	Oct. 31, 2017	Jul. 31, 2017	Apr. 30, 2017
Inventory [Line Items]
Inventories	$ 16,672			$ 18,549
Total Current Assets	59,756			64,391
Deferred income taxes	1,676			1,869
Total Assets	79,562			85,083
Other accrued expenses	2,894			2,116
Total Current Liabilities	23,706			27,616
Total Liabilities	30,051			36,891
Retained earnings	45,345			43,836
Total Kewaunee Scientific Corporation Stockholders’ Equity	48,990	$ 48,920	$ 48,611	47,730	$ 46,278	$ 45,515	$ 44,347	$ 43,461
Total Stockholders’ Equity	49,511			48,192
Total Liabilities and Stockholders’ Equity	79,562			85,083
As Reported
Inventory [Line Items]
Inventories	15,634
Total Current Assets	58,718
Deferred income taxes	1,838
Total Assets	78,686
Other accrued expenses	2,803
Total Current Liabilities	23,615
Total Liabilities	29,960
Retained earnings	44,560
Total Kewaunee Scientific Corporation Stockholders’ Equity	48,205
Total Stockholders’ Equity	48,726
Total Liabilities and Stockholders’ Equity	78,686
Adjustments
Inventory [Line Items]
Inventories	(1,038)			887
Total Current Assets	(1,038)			887
Deferred income taxes	162			(162)
Total Assets	(876)			725
Other accrued expenses	(91)			54
Total Current Liabilities	(91)			54
Total Liabilities	(91)			54
Retained earnings				671
Total Kewaunee Scientific Corporation Stockholders’ Equity	(785)			671
Total Stockholders’ Equity	(785)			671
Total Liabilities and Stockholders’ Equity	(876)			725
As Reported Under FIFO
Inventory [Line Items]
Inventories	$ 16,672			17,662
Total Current Assets				63,504
Deferred income taxes				2,031
Total Assets				84,358
Other accrued expenses				2,062
Total Current Liabilities				27,562
Total Liabilities				36,837
Retained earnings				43,165
Total Kewaunee Scientific Corporation Stockholders’ Equity				47,059
Total Stockholders’ Equity				47,521
Total Liabilities and Stockholders’ Equity				$ 84,358

Inventories - Schedule of Imp_2

Inventories - Schedule of Impact on the Company's Condensed Consolidated Statements of Operations (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended						9 Months Ended
	Jan. 31, 2019	Oct. 31, 2018	Jul. 31, 2018	Jan. 31, 2018	Oct. 31, 2017	Jul. 31, 2017	Jan. 31, 2019	Jan. 31, 2018
Inventory [Line Items]
Cost of products sold	$ 27,142			$ 29,791			$ 91,325	$ 90,411
Income tax expense	20			1,581			803	3,164
Net earnings	15			948			2,885	3,905
Net earnings attributable to Kewaunee Scientific Corporation	$ (22)	$ 1,414	$ 1,407	$ 913	$ 1,724	$ 1,148	$ 2,799	$ 3,785
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic (in dollars per share)	$ (0.01)			$ 0.33			$ 1.02	$ 1.39
Diluted (in dollars per share)	$ (0.01)			$ 0.32			$ 1	$ 1.36
As Reported
Inventory [Line Items]
Cost of products sold	$ 27,093			$ 29,836			$ 91,476	$ 90,456
Income tax expense	32			1,566			766	3,149
Net earnings	52			918			2,771	3,875
Net earnings attributable to Kewaunee Scientific Corporation	$ 15			$ 883			$ 2,685	$ 3,755
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic (in dollars per share)	$ 0			$ 0.32			$ 0.98	$ 1.38
Diluted (in dollars per share)	$ 0			$ 0.31			$ 0.96	$ 1.35
Adjustments
Inventory [Line Items]
Cost of products sold	$ (49)			$ (45)			$ 151	$ (45)
Income tax expense	12			15			(37)	15
Net earnings	37			30			(114)	30
Net earnings attributable to Kewaunee Scientific Corporation	$ 37			$ 30			$ (114)	$ 30
Net earnings per share attributable to Kewaunee Scientific Corporation stockholders
Basic (in dollars per share)	$ 0.01			$ 0.01			$ (0.04)	$ 0.01
Diluted (in dollars per share)	$ 0.01			$ 0.01			$ (0.04)	$ 0.01

Inventories - Schedule of Imp_3

Inventories - Schedule of Impact on the Company's Condensed Consolidated Statement of Cash Flows (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Inventory [Line Items]
Net earnings	$ 15	$ 948	$ 2,885	$ 3,905
Decrease in inventories			990	(2,790)
Increase in accounts payable and other accrued expenses			(4,879)	2,035
Net cash used in operating activities			4,534	(645)
Adjustments
Inventory [Line Items]
Net earnings	37	30	(114)	30
Decrease in inventories			151	(45)
Increase in accounts payable and other accrued expenses			(37)	15
Net cash used in operating activities			0	0
As Computed Under LIFO
Inventory [Line Items]
Net earnings	$ 52	$ 918	2,771	3,875
Decrease in inventories			1,141	(2,745)
Increase in accounts payable and other accrued expenses			(4,916)	2,020
Net cash used in operating activities			$ 4,534	$ (645)

Segment Information - Additiona

Segment Information - Additional Information (Detail)	9 Months Ended
	Jan. 31, 2019Segment
Segment Reporting [Abstract]
Number of business segment	2

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Segment Reporting Information [Line Items]
Revenues from external customers	$ 32,372	$ 38,190	$ 111,802	$ 113,542
Intersegment revenues	0	0	0	0
Earnings (loss) before income taxes	35	2,529	3,688	7,069
Corporate / Eliminations
Segment Reporting Information [Line Items]
Revenues from external customers	0	0	0	0
Intersegment revenues	(2,747)	(2,506)	(5,459)	(13,589)
Earnings (loss) before income taxes	(1,045)	(1,838)	(4,491)	(4,715)
Domestic Operations | Operating Segments
Segment Reporting Information [Line Items]
Revenues from external customers	25,217	29,734	91,909	80,420
Intersegment revenues	612	1,145	1,490	10,298
Earnings (loss) before income taxes	60	3,004	6,005	7,765
International Operations | Operating Segments
Segment Reporting Information [Line Items]
Revenues from external customers	7,155	8,456	19,893	33,122
Intersegment revenues	2,135	1,361	3,969	3,291
Earnings (loss) before income taxes	$ 1,020	$ 1,363	$ 2,174	$ 4,019

Defined Benefit Pension Plans -

Defined Benefit Pension Plans - Additional Information (Detail) - USD ($)	9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Retirement Benefits [Abstract]
Employer contributions paid during the remainder of fiscal year	$ 0
Employer contributions	$ 1,000,000	$ 600,000
Assumed as expected long-term rate of return	7.75%	7.75%

Defined Benefit Pension Plans_2

Defined Benefit Pension Plans - Pension Expenses (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Retirement Benefits [Abstract]
Service cost	$ 0	$ 0	$ 0	$ 0
Interest cost	214	219	644	657
Expected return on plan assets	(362)	(328)	(1,086)	(984)
Recognition of net loss	221	283	663	849
Net periodic pension expense	$ 73	$ 174	$ 221	$ 522

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis (Detail) - USD ($) $ in Thousands	Jan. 31, 2019	Apr. 30, 2018
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	$ 2,883	$ 4,115
Financial Liabilities		4,467
Interest rate swap derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities		5
Non Qualified Compensation Plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities	3,256	4,462
Trading Securities Held in Non-Qualified Compensation Plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	2,818	4,050
Cash Surrender Value of Life Insurance Policies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	65	65
Level 1
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	2,818	4,050
Financial Liabilities		0
Level 1 | Interest rate swap derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities		0
Level 1 | Non Qualified Compensation Plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities	0	0
Level 1 | Trading Securities Held in Non-Qualified Compensation Plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	2,818	4,050
Level 1 | Cash Surrender Value of Life Insurance Policies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	0	0
Level 2
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	65	65
Financial Liabilities		4,467
Level 2 | Interest rate swap derivatives
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities		5
Level 2 | Non Qualified Compensation Plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Liabilities	3,256	4,462
Level 2 | Trading Securities Held in Non-Qualified Compensation Plans
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	0	0
Level 2 | Cash Surrender Value of Life Insurance Policies
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Financial Assets	$ 65	$ 65

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Summary of Fair Value Hierarchy for Financial Assets and Liabilities Measured Recurring Basis, Phantom (Detail)	Apr. 30, 2018CompensationPlan
Fair Value Disclosures [Abstract]
Number of non-qualified compensation plans maintained	2

Stock Options and Share-Based_2

Stock Options and Share-Based Compensation - Additional Information (Detail) - 2017 Plan - Restricted Stock Units (RSUs) - USD ($)	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2018	Jan. 31, 2019	Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock units granted	17,769
Vesting period			3 years
Stock-based compensation expense		$ 45,000	$ 106,000
Remaining estimated compensation expense		$ 406,000	$ 406,000